Cargando…

Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival

The number of long-term survivors of high-risk neuroblastoma remains discouraging, with 10-year survival as low as 20%, despite decades of considerable international efforts to improve outcome. Major obstacles remain and include managing resistance to induction therapy, which causes tumor progressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Thole, Theresa M, Lodrini, Marco, Fabian, Johannes, Wuenschel, Jasmin, Pfeil, Sebastian, Hielscher, Thomas, Kopp-Schneider, Annette, Heinicke, Ulrike, Fulda, Simone, Witt, Olaf, Eggert, Angelika, Fischer, Matthias, Deubzer, Hedwig E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386552/
https://www.ncbi.nlm.nih.gov/pubmed/28252645
http://dx.doi.org/10.1038/cddis.2017.49
_version_ 1782520787997032448
author Thole, Theresa M
Lodrini, Marco
Fabian, Johannes
Wuenschel, Jasmin
Pfeil, Sebastian
Hielscher, Thomas
Kopp-Schneider, Annette
Heinicke, Ulrike
Fulda, Simone
Witt, Olaf
Eggert, Angelika
Fischer, Matthias
Deubzer, Hedwig E
author_facet Thole, Theresa M
Lodrini, Marco
Fabian, Johannes
Wuenschel, Jasmin
Pfeil, Sebastian
Hielscher, Thomas
Kopp-Schneider, Annette
Heinicke, Ulrike
Fulda, Simone
Witt, Olaf
Eggert, Angelika
Fischer, Matthias
Deubzer, Hedwig E
author_sort Thole, Theresa M
collection PubMed
description The number of long-term survivors of high-risk neuroblastoma remains discouraging, with 10-year survival as low as 20%, despite decades of considerable international efforts to improve outcome. Major obstacles remain and include managing resistance to induction therapy, which causes tumor progression and early death in high-risk patients, and managing chemotherapy-resistant relapses, which can occur years after the initial diagnosis. Identifying and validating novel therapeutic targets is essential to improve treatment. Delineating and deciphering specific functions of single histone deacetylases in neuroblastoma may support development of targeted acetylome-modifying therapeutics for patients with molecularly defined high-risk neuroblastoma profiles. We show here that HDAC11 depletion in MYCN-driven neuroblastoma cell lines strongly induces cell death, mostly mediated by apoptotic programs. Genes necessary for mitotic cell cycle progression and cell division were most prominently enriched in at least two of three time points in whole-genome expression data combined from two cell systems, and all nine genes in these functional categories were strongly repressed, including CENPA, KIF14, KIF23 and RACGAP1. Enforced expression of one selected candidate, RACGAP1, partially rescued the induction of apoptosis caused by HDAC11 depletion. High-level expression of all nine genes in primary neuroblastomas significantly correlated with unfavorable overall and event-free survival in patients, suggesting a role in mediating the more aggressive biological and clinical phenotype of these tumors. Our study identified a group of cell cycle-promoting genes regulated by HDAC11, being both predictors of unfavorable patient outcome and essential for tumor cell viability. The data indicate a significant role of HDAC11 for mitotic cell cycle progression and survival of MYCN-amplified neuroblastoma cells, and suggests that HDAC11 could be a valuable drug target.
format Online
Article
Text
id pubmed-5386552
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53865522017-04-27 Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival Thole, Theresa M Lodrini, Marco Fabian, Johannes Wuenschel, Jasmin Pfeil, Sebastian Hielscher, Thomas Kopp-Schneider, Annette Heinicke, Ulrike Fulda, Simone Witt, Olaf Eggert, Angelika Fischer, Matthias Deubzer, Hedwig E Cell Death Dis Original Article The number of long-term survivors of high-risk neuroblastoma remains discouraging, with 10-year survival as low as 20%, despite decades of considerable international efforts to improve outcome. Major obstacles remain and include managing resistance to induction therapy, which causes tumor progression and early death in high-risk patients, and managing chemotherapy-resistant relapses, which can occur years after the initial diagnosis. Identifying and validating novel therapeutic targets is essential to improve treatment. Delineating and deciphering specific functions of single histone deacetylases in neuroblastoma may support development of targeted acetylome-modifying therapeutics for patients with molecularly defined high-risk neuroblastoma profiles. We show here that HDAC11 depletion in MYCN-driven neuroblastoma cell lines strongly induces cell death, mostly mediated by apoptotic programs. Genes necessary for mitotic cell cycle progression and cell division were most prominently enriched in at least two of three time points in whole-genome expression data combined from two cell systems, and all nine genes in these functional categories were strongly repressed, including CENPA, KIF14, KIF23 and RACGAP1. Enforced expression of one selected candidate, RACGAP1, partially rescued the induction of apoptosis caused by HDAC11 depletion. High-level expression of all nine genes in primary neuroblastomas significantly correlated with unfavorable overall and event-free survival in patients, suggesting a role in mediating the more aggressive biological and clinical phenotype of these tumors. Our study identified a group of cell cycle-promoting genes regulated by HDAC11, being both predictors of unfavorable patient outcome and essential for tumor cell viability. The data indicate a significant role of HDAC11 for mitotic cell cycle progression and survival of MYCN-amplified neuroblastoma cells, and suggests that HDAC11 could be a valuable drug target. Nature Publishing Group 2017-03 2017-03-02 /pmc/articles/PMC5386552/ /pubmed/28252645 http://dx.doi.org/10.1038/cddis.2017.49 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Original Article
Thole, Theresa M
Lodrini, Marco
Fabian, Johannes
Wuenschel, Jasmin
Pfeil, Sebastian
Hielscher, Thomas
Kopp-Schneider, Annette
Heinicke, Ulrike
Fulda, Simone
Witt, Olaf
Eggert, Angelika
Fischer, Matthias
Deubzer, Hedwig E
Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival
title Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival
title_full Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival
title_fullStr Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival
title_full_unstemmed Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival
title_short Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival
title_sort neuroblastoma cells depend on hdac11 for mitotic cell cycle progression and survival
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386552/
https://www.ncbi.nlm.nih.gov/pubmed/28252645
http://dx.doi.org/10.1038/cddis.2017.49
work_keys_str_mv AT tholetheresam neuroblastomacellsdependonhdac11formitoticcellcycleprogressionandsurvival
AT lodrinimarco neuroblastomacellsdependonhdac11formitoticcellcycleprogressionandsurvival
AT fabianjohannes neuroblastomacellsdependonhdac11formitoticcellcycleprogressionandsurvival
AT wuenscheljasmin neuroblastomacellsdependonhdac11formitoticcellcycleprogressionandsurvival
AT pfeilsebastian neuroblastomacellsdependonhdac11formitoticcellcycleprogressionandsurvival
AT hielscherthomas neuroblastomacellsdependonhdac11formitoticcellcycleprogressionandsurvival
AT koppschneiderannette neuroblastomacellsdependonhdac11formitoticcellcycleprogressionandsurvival
AT heinickeulrike neuroblastomacellsdependonhdac11formitoticcellcycleprogressionandsurvival
AT fuldasimone neuroblastomacellsdependonhdac11formitoticcellcycleprogressionandsurvival
AT wittolaf neuroblastomacellsdependonhdac11formitoticcellcycleprogressionandsurvival
AT eggertangelika neuroblastomacellsdependonhdac11formitoticcellcycleprogressionandsurvival
AT fischermatthias neuroblastomacellsdependonhdac11formitoticcellcycleprogressionandsurvival
AT deubzerhedwige neuroblastomacellsdependonhdac11formitoticcellcycleprogressionandsurvival